Artur Martynov, Pharm.D, PhD.,Sc.D., Professor, head of laboratory

Olena Grishyna, MD, PhD., leader researcher (head of
clinical division)


Yury Lisnyak, Mat.D., PhD., leader researcher (head of molecular design division) 


Romanova Helen, BD., PhD., leader researcher, (head of immunology division)


Bomko Tatyana, BD., PhD., leader researcher  (head of preclinical research division)


Nosalskaya Tatyana, BD.,
PhD., leader researcher


Kabluchko Tatyana, Senior Assistant


Pogorelaya Marina, senior researcher

Shcherbak Olga, MD., PhD., senior researcher

Batrak Helen, Pharm.D., PhD., senior researcher

Sidorenko Tatyana., senior researcher

Igumnova Nataly, senior researcher

Menkus Helen, researcher

Yukhimenko Vera, researcher

Babinets Olga, junior researcher



Our Partners:


 [Farber's Center for Academic Success LLC & Noigel LLC]
 (New-York, USA)


 [School of Medicine of V. N. Karazin Kharkiv National University]
 (Kharkov, Ukraine)

 [North-East Scientific Center of NAS and MES of Ukraine ]
 (Kharkov, Ukraine)


 [Kavetsky Institute of Experimental Pathology, Oncology
 and Radiobiology, NASU]

 (Kiev, Ukraine)


 [National University of Pharmacy,dpt. of Chemistry of Natural Compounds]
 (Kharkov, Ukraine)


 [Kharkiv City Multidisciplinary Hospital №18] 


Priority areas:

 Medicine areas: rheumatoid arthritis; metabolic syndrome; immune system misbalance in somatic pathology;  after vaccination immunity; autoimmune pathology; new drugs and drugs combination in development; new diagnostic methods; clinical study the new drugs and substances (State Agreement for clinical base)

 Pharmacology & Pharmacy areas: drug-design for new antimicrobial, antiviral; anticancer substances; computer modelling of biomolecular systems, structural aspects of biological activity, design for dynamic drugs (self-assembled therapeutical systems); in vitro and in vivo preclinical study the new substances (State Certificate 2015-2018)

 Organic & Electro - chemistry: immunochemical biosensors; bioelectrochemical Ag-Cu catalysis; new Ag-Cu - containing antiseptics for veterinary and agriculture; synthesis and study of quasi-living self-assembled and self-organized system

 Current State Grants from NAMSU:

1. "The action of influenza vaccination on the course of comorbid conditions in patients with metabolic syndrome"

2. "Studies of interactions between mycobacterial urease and supramolecular systems based on combinatorial derived polyphenols"

3. "Creation of new prevention drugs for preventing reactivation of latent tuberculosis"

Recent projects:

1. Molecular modeling and simulations of supramolecular complexes of antimicrobial compounds with additive and model substances /2004-2006/
2. Experimental and theoretical study of the inclusion complexation of cyclodextrins and their functionalized derivatives with biomolecules /2007-2009/
3. The study of structure-function relations of peptide antibiotics /2010-2012/



 1. Grishyna, О. I. Apixaban in patients with atrial fibrillation [Text] / О. I. Grishyna, AVERROES Steering Committee and Investigators, S. J. Connolly, J. Eikelboom et al // The New England Journal of Medicine. – 2011. Vol. 364, N 9, P. 806817.

 2.  Grishyna, О. I. Tiotropium versus salmeterol for the prevention of exacerbations of COPD [Text] / О. I. Grishyna A., POET-COPD Investigators, C. Vogelmeier, B. Hederer et al // The New England Journal of Medicine. – 2011. Vol. 364, N 12, P. 10931103.

 3.  Grishyna, О. I. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation [Text] / О. I. Grishyna, ROCKET AF Investigators, M. R. Patel, K. W. Mahaffey et al // The New England Journal of Medicine. – 2011. Vol. 365, N 10, P. 883891.

 4.  Grishyna, О. I. Apixaban versus aspirin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a predefined subgroup analysis from AVERROES, a randomised trial [Text] /  О. I. Grishyna, AVERROES Steering Committee and Investigators, H. C. Diener, J. Eikelboom et al // Lancet Neurol. – 2012. Vol. 11, N 3, P. 225231.

 5. Grishyna, О. I. Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF [Text] / О. I. Grishyna, ROCKET AF Steering Committee Investigators, G. J. Hankey, M. R. Patel et al // Lancet Neurol. – 2012. Vol. 11, N 4, P. 315322.

 6.  Grishyna, О. I. Diet and kidney disease in high-risk individuals with type 2 diabetes mellitus [Text] / О. I. Grishyna, ONTARGET Investigators, D. Dunkler, M. Dehghan et al // JAMA Intern Med. – 2013. Vol. 173, N 18, P. 16821692

 7.Grishyna, О. I. Variations in Cause and Management of Atrial Fibrillation in a Prospective Registry of 15,400 Emergency Department Patients in 46 Countries: The RE-LY AF Registry [Text] / О. I. Grishyna, RE-LY Atrial Fibrillation Registry Investigators, J. Oldgren, J. S. Healey et al // Circulation. – 2014. – Vol. 129, N 15. – P. 1568-1576

 8. Grishyna, О. I. Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF) [Text] / О. I. Grishyna, ROCKET AF Investigators, J. L. Halperin, G. J. Hankey et al // Circulation. – 2014. – Vol. 130, N 2. – P. 138-146

9. Martynov A, Farber B, Farber S. Quasi-life self-organizing systems: based on ensembles of succinylated derivatives of interferon-gamma. Curr Med Chem. 2011;18(22):3431-6.

10. Yuriy V. Lisnyak, Arthur V. Martynov , Vyacheslav N. Baumer, Oleg V. Shishkin and Anna V. Gubskaya. Crystal and molecular structure of β-cyclodextrin inclusion complex with succinic acid // Journal of Inclusion Phenomena and Macrocyclic Chemistry.- 2007.- Volume 58, Numbers 3-4, P. 367-375, DOI 10.1007/s10847-006-9284-x

11. Schemchuk L.A., Chernych V.P., Martynov A.V. Synthesis of trans-aconitic acid imides //RJOC.- 1997.-Vol.33, N 3.-P.1257-1259

12. Martynov A.V., Shmatko Yu.V., Smelyanskaya M.V., Peremot S.D., Vinnik Yu.M. Detection of herpes virus type 1 antigen in lymphocytes and tumor tissue of patients with cancer of uterus // Exp. Oncology. - 2002.- Vol. 24, N 2. – P.120-122

13. Kuchma I.Yu., Volyansky A.Yu., Moskalenko V.F., Tkachuk T.B., Dobroskok A.I., Martynov A.V., Smelyanskaya M.V., Peremot S.D. Using of cis-aconitic acid phenylimides in liposomal form for herpes treatment // J. Micr.Epid.Immunobiol.-2000.- N 5.- P.58-61

14. Martynov AV, Tymchenko OM, Pokhyl SI. Chemically modified specific immunoglobulins for legionellosis laboratory diagnostics Mikrobiol Z. 2005 May-Jun;67(3):61-70.

15. Мartynov А.V., Smelyanskaya M.V. Antiproliferative properties of chemically modified a-2b-recombinant interferon // J. of Interf. & Cytokine res.- 2005.-Vol. 25, N 7.- P. 414-417

16. Martynov A.V. New approach to synthesis of trans-aconitic acid imides // RJOC.-2005.-41(5).- P. 731-734

17. Martynov AV, Tymchenko OM, Pokhyl SI. Effect of succinylation of Klebsiella 45 bacteriophage proteins on specific lytic activity. Mikrobiol Z. 2005 Sep-Oct;67(5):80-8.

18. Martynov AV, Bomko TV,  Nosalskaya TN,   Farber BS, Farber SB. Oral long-acting pharmaceutical form of insulin on the basis of self-organizing kvasi-living system of combinatorial peptides// Annals of Mechnikov Institute, N 2, 2012.-P.64-70

19. Martynov AV,Farber  BS, Farber  SB. The use of antiviral drugs for treatment of cancer patients// Allergy. -2011. -66, Suppl.94.-P.661-662 (Abstr. Conf.)

Martynov AV,Farber  BS, Farber  SB. A new anti-viral drug with a quick, direct effect// 2011 FIP Congress in Hyderabad (India).- Sept.,5.-P.1. (Abstr. Conf.)

21. Martynov AV,Farber  BS, Farber  SB A method useable in clinics for significantly increasing the effectiveness of treating patients with malignant tumors // European journal of Internal medicine.-2011.-Vol.22, Suppl.1.-P. 29-31 //10th Congress of the European Federation of Internal Medicine 5 October - 8 October 2011, Athens Hilton Hotel, Greece (Abstr. Conf.)
Martynov AV,Farber  BS, Farber  SB. A new anticancer drug overcomes cancer resistance// FOCIS.-2011.- Abs.Suppl. Washington, June 23-26.- P.122-123  (Abstr. Conf.)
US Patent 8846064B2. Cosmetic and pharmaceutical compositions having modified proteins in the form of a supramolecular assembly// Martynov AV,Farber  BS, Farber  SB./ Publ. 30.09.2014. Prior. 02.08.2012

24. Lisnyak Yu.V., Martynov A.V. Molecular modeling of interactions of antimicrobial compounds with cell membrane components: nystatin-ergosterol membrane pore // Annals of Mechnikov’s Institute. – 2012. - № 3. – P. 51-56.

25. Lisnyak Yu.V. Models of amphotericin membrane channel based on concerted  =C-HO intermolecular interactions // Annals of Mechnikov’s Institute. – 2012. - № 3. – P. 33-37.

26. Gubskaya A. V., Khan I. J., Valenzuela L. M., Lisnyak Yu. V., Kohn J. Investigating the release of a hydrophobic peptide from matrices of biodegradable polymers: an integrated method approach // Polymer. - 2013. – Vol. 54, N 15. – P. 3806-3820.

27. Lisnyak Yu.V. Molecular modeling study of the contributions of side amino acid residues of polymyxin B3 to its binding with E.coli outer membrane lipopolysaccharide // Annals of Mechnikov’s Institute. – 2014. – N4. – P. 44-54.

28. Lisnyak Yu. V. Molecular targets of nephrotoxic action of polymyxins // Annals of Mechnikov’s Institute. – 2015. – N3. – P. 8-24.  

29. Lisnyak Yu. V.  Molecular dynamics study of interactions of polymyxin B3 and its Ala-mutants with lipopolysaccharide // Annals of Mechnikov’s Institute. – 2015. – N4.



Address: 14-Puskhinskaya St.,
               Kharkov, Ukraine,
               IMI of NAMS